BioPharma Dive8d
Tris to ask for approval of dual-acting pain drug
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
Clinical Trials Arena on MSN7d
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.
Hosted on MSN8mon
Ketan Mehta Calls for Indian Animation Caught in a ‘Vicious Cycle' to Adopt ‘Global Mindset' – Mumbai Festival
Ketan Mehta, the revered Indian filmmaker who also serves as founder and chair of animation house Cosmos-Maya, known for long-running animated Nickelodeon show "Motu Patlu," says that the global ...
Business Wire8d
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Trea…
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
Fierce Biotech8d
Tris' next-gen pain drug completes trio of clinical wins, setting up push to FDA
Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...
Applied Clinical Trials Online8d
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...